• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of amjphAmerican Journal of Public Health Web SiteAmerican Public Health Association Web SiteSubmissionsSubscriptionsAbout Us
Am J Public Health. 1996 December; 86(12): 1709–1712.
PMCID: PMC1380721

The cost-effectiveness of HIV prevention targeting: how much more bang for the buck?


BACKGROUND: Although the targeting of human immunodeficiency virus (HIV) prevention to high-risk populations has been widely discussed, its benefits have not been quantified. METHODS: This analysis of cost-effectiveness combines an HIV epidemic model, target population scenarios, and data on the cost and impact of prevention. RESULTS: The number of HIV infections averted in 5 years with $1 million in annual prevention spending ranges from 164 in high-risk populations to 0.4 in very-low-risk populations. Fortyfold to two-hundredfold differences in prevention costs could equalize HIV infections averted. CONCLUSIONS: Targeting appears to provide substantial benefit and should be considered in allocation decisions about prevention.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.1M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Des Jarlais DC, Padian NS, Winkelstein W., Jr Targeted HIV-prevention programs. N Engl J Med. 1994 Nov 24;331(21):1451–1453. [PubMed]
  • Stryker J, Bayer R. AIDS policy: two divisive issues. JAMA. 1993 Nov 24;270(20):2436–2437. [PubMed]
  • Rogers DE, Osborn JE. AIDS policy. Two divisive issues. JAMA. 1993 Jul 28;270(4):494–495. [PubMed]
  • Holtgrave DR, Qualls NL, Curran JW, Valdiserri RO, Guinan ME, Parra WC. An overview of the effectiveness and efficiency of HIV prevention programs. Public Health Rep. 1995 Mar-Apr;110(2):134–146. [PMC free article] [PubMed]
  • Vermund SH. Decision making for clinical trials and prevention research: commentary on the model of Paltiel and Kaplan. J Acquir Immune Defic Syndr. 1993 Feb;6(2):176–178. [PubMed]
  • Siegel JE, Weinstein MC, Fineberg HV. Bleach programs for preventing AIDS among i.v. drug users: modeling the impact of HIV prevalence. Am J Public Health. 1991 Oct;81(10):1273–1279. [PMC free article] [PubMed]
  • Osmond DH, Page K, Wiley J, Garrett K, Sheppard HW, Moss AR, Schrager L, Winkelstein W. HIV infection in homosexual and bisexual men 18 to 29 years of age: the San Francisco Young Men's Health Study. Am J Public Health. 1994 Dec;84(12):1933–1937. [PMC free article] [PubMed]
  • Lemp GF, Hirozawa AM, Givertz D, Nieri GN, Anderson L, Lindegren ML, Janssen RS, Katz M. Seroprevalence of HIV and risk behaviors among young homosexual and bisexual men. The San Francisco/Berkeley Young Men's Survey. JAMA. 1994 Aug 10;272(6):449–454. [PubMed]
  • Zolopa AR, Hahn JA, Gorter R, Miranda J, Wlodarczyk D, Peterson J, Pilote L, Moss AR. HIV and tuberculosis infection in San Francisco's homeless adults. Prevalence and risk factors in a representative sample. JAMA. 1994 Aug 10;272(6):455–461. [PubMed]
  • Des Jarlais DC, Friedman SR, Sotheran JL, Wenston J, Marmor M, Yancovitz SR, Frank B, Beatrice S, Mildvan D. Continuity and change within an HIV epidemic. Injecting drug users in New York City, 1984 through 1992. JAMA. 1994 Jan 12;271(2):121–127. [PubMed]
  • Moss AR, Vranizan K, Gorter R, Bacchetti P, Watters J, Osmond D. HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. AIDS. 1994 Feb;8(2):223–231. [PubMed]
  • Choi KH, Coates TJ. Prevention of HIV infection. AIDS. 1994 Oct;8(10):1371–1389. [PubMed]
  • Booth RE, Watters JK. How effective are risk-reduction interventions targeting injecting drug users? AIDS. 1994 Nov;8(11):1515–1524. [PubMed]
  • Friedman SR, Des Jarlais DC. HIV among drug injectors: the epidemic and the response. AIDS Care. 1991;3(3):239–250. [PubMed]
  • Des Jarlais DC, Hagan H, Friedman SR, Friedmann P, Goldberg D, Frischer M, Green S, Tunving K, Ljungberg B, Wodak A, et al. Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA. 1995 Oct 18;274(15):1226–1231. [PubMed]

Articles from American Journal of Public Health are provided here courtesy of American Public Health Association


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Cited in Books
    Cited in Books
    PubMed Central articles cited in books
  • PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...